NasdaqHealth CarePharmaceutical PreparationsVANCOUVER, British Columbia, Canada

Eupraxia Pharmaceuticals Inc. EPRX

Ask your AI

Estimated market cap $423.30M51.94M shares, shares as of Dec 31, 2025CIK 1581178

Insider trades, 12 mo

—

No open-market trades

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q2 2026

47.8% of shares · 22 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

What changed in Eupraxia Pharmaceuticals Inc.'s latest quarterly report, compared with the one before.

We have not read a recent 10-Q for this company yet.

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No recent insider purchases or sales for this company.

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

24.81M shares

68 funds report EPRX. Values checked against market prices.

Funds own 48% of shares (Q2 2026)

68 funds hold the stock.

Q3 2026: 20% · 5,560 of ~8,900 funds reported so far

Q2 20256.7%
Q3 202525%
Q4 202527%
Q1 202643%
Q2 202648%
Q3 2026 (so far)20%

Reports for the quarter ending Sep 30, 2026 are still coming in (34 positions so far, against 70 the quarter before), so we compare the two complete quarters before it.

Q2 2026. 18 new, 22 added to, 18 trimmed, 5 exited since Q1 2026.

Top 13F holders
#
1	Beutel, Goodman & Co Ltd. 13F ↗	3.63M	$23.8M	-1.1%
2	Affinity Asset Advisors, LLC 13F ↗	1.65M	$10.9M	+3.8%
3	Balyasny Asset Management L.P. 13F ↗	1.35M	$8.9M	unchanged
4	Vivo Capital, LLC 13F ↗	1.35M	$8.9M	unchanged
5	Scotia Capital Inc. 13F ↗	1.34M	$8.8M	+0.1%
6	PFM Health Sciences, LP 13F ↗	1.21M	$8.0M	+123.8%
7	Great Point Partners LLC 13F ↗	1.20M	$7.9M	unchanged
8	Jupiter Topco LLC 13F ↗	1.05M	$6.9M	New
9	Rubric Capital Management LP 13F ↗	867,424	$5.7M	+25.5%
10	Ikarian Capital, LLC 13F ↗	809,741	$5.4M	-33.3%

One of these funds reports its values in thousands of dollars; its figures are shown in dollars.

Download CSV Every fund that holds EPRX, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Eupraxia Pharmaceuticals Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Eupraxia Pharmaceuticals Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q2 2024	8	—	1.73M	$4.4M
Q3 2024	8	0	1.80M	$4.5M
Q4 2024	9	+1	1.83M	$5.6M
Q1 2025	11	+2	2.17M	$7.1M
Q2 2025	14	+3	2.40M	$13.4M
Q3 2025	27	+13	12.83M	$75.4M
Q4 2025	36	+9	13.95M	$105.1M
Q1 2026	55	+19	22.23M	$158.3M
Q2 2026	68	+13	24.81M	$163.6M
Q3 2026	34	-34	10.61M	$96.6M

Each point is a quarter-end, from Q2 2024 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (29842P105). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2024) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes4 in 12 mo 8-K eventsNone in 90 days Patents2 patents granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials1 active Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: EUPRAXIA PHARMACEUTICALS INC.
Address: 2198 YUKON STREET, VANCOUVER, British Columbia, Canada V5Y 3P1
Phone: 250-590-3968
Fiscal year ends: Dec 31
Filer category: emerging growth company
Incorporated in: British Columbia, Canada
Listed as: EPRX (Nasdaq)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$8.15+$0.34 (+4.35%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $6.59 · High $8.15Nov 13, 2026

Aug 13, 2026Low $6.34 · High $9.10Nov 13, 2026

Nov 13, 2025Low $5.81 · High $9.10Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.